Study Details

Back
Study ID 015K-CL-PS01
Study Title A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects with Moderate to Severe Plaque Psoriasis
Clinicaltrials.gov Identifier NCT01096862
Compound Name ASP015K / peficitinib hydrobromide
Medical Indication or Disease Psoriasis
Study Sponsor Astellas Pharma Global Development, Inc. (APGD)
Collaborator Not Applicable
Study Start Date 23-Mar-2010
Study Completion Date 27-Jul-2011
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS